Methodology
GLP-1 Pricing Verification Methodology
The whole rubric, in public, with the arithmetic. If you disagree with a score, you should be able to point at the exact category and the exact missing evidence.
A price on this site is the lowest monthly figure a program prints on its own page for the stated plan, read on a stated date, with every required fee added and an annual membership spread over twelve months. Figures we could not re-read keep their original date and are marked as older records.
Show this figure as a table
| Category | Points |
|---|---|
| Pricing transparency | 20 pts |
| Total annual cost | 20 pts |
| Clinical oversight | 15 pts |
| Pharmacy transparency | 15 pts |
| Support | 10 pts |
| Regulatory disclosure | 10 pts |
| Accessibility | 10 pts |
Rules that override any score
- No provider may purchase points, placement, or a review.
- Missing evidence scores lower than evidence we checked ourselves. Absence is never scored as neutral.
- Provider-reported evidence is labelled as provider-reported wherever it appears.
- Prices are never compared across different program types. Starter, ongoing, maintenance, dose-tier, prepaid and month-to-month are scored separately.
- Microdose programs are never scored against standard-dose programs.
- Oral, sublingual and ODT compounded products are separated from injectables and carry an explicit evidence-limitation label.
- Category weights and the arithmetic are published here; category breakdowns are added to provider pages as re-scores are completed.
- Rankings are recomputed when material evidence changes, not on a marketing calendar.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Locate the published price | The provider's own page or checkout, never an aggregator. |
| 2 | Capture with a timestamp | Screenshot or archive stored against an evidence ID. |
| 3 | Itemise every required fee | Membership, shipping, consultation, labs, dose surcharge. |
| 4 | Classify the program | Starter, ongoing, maintenance, prepaid or month-to-month. |
| 5 | Normalise to monthly equivalent | Our arithmetic, applied identically to every provider. |
| 6 | Second-reviewer check | A different person re-opens the source and confirms the figure. |
| 7 | Set a next-review date | The figure is marked outdated when that date passes. |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Lowest claim | Highest claim |
|---|---|---|
| Henry Meds (third-party claim) | $179 | $549 |
| Hims & Hers (third-party claim) | $299 | $549 |
| Mochi Health (third-party claim) | $229 | $308 |
| Ro (third-party claim) | $199 | $349 |
| Provider and stated basis | Figure published | Where it was published |
|---|---|---|
| Henry Meds — from | $199/month | peptidesexplorer.com (third-party claim) |
| Henry Meds — introductory month | $297/month | trimrx.com (third-party claim) |
| Henry Meds — flat monthly | $449/month | formblends.com (third-party claim) |
| Henry Meds — maintenance dose, upper end | $549/month | trimrx.com (third-party claim) |
| Hims & Hers — introductory | $299/month | trimrx.com (third-party claim) |
| Hims & Hers — maintenance dose, upper end | $549/month | trimrx.com (third-party claim) |
How a category is scored
Two of the seven v4.1 categories rest directly on price evidence, and together they carry 40 of the 100 points.
- Pricing transparency (20 points) asks whether you can see what you will pay before you hand over any details. That means every dose and plan priced on the provider's own page, the required fees listed, and the terms stated: month to month, prepaid or sale. A price that only appears after intake or at checkout scores lower than one shown openly.
- Total annual cost (20 points) asks what twelve months cost at a maintenance dose, with every required fee included.
A price counts only after seven steps. We locate it on the seller's own page, capture it with a timestamp, itemise every fee, classify the program type, convert to a monthly equivalent, have a second reviewer re-open the source, and set a next-review date. A figure that has not passed the second-reviewer check is labelled provider-reported, not verified.
Worked example, read November 6, 2026: NexLife charges $129 month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans. That is $1,380 for 12 months, at the same price at every dose, with no membership fee.
How prices are normalised before comparison
The arithmetic, with figures from the price records:
| Listed as | Recorded as | Monthly equivalent |
|---|---|---|
| $129 a month, month to month (NexLife) | Month to month | $129 |
| $1,380 for 12 months (NexLife) | Prepaid, 12 months | $115 |
| $114 a month, six months paid up front (Mondae) | Prepaid, 6 months | $114, compared only with prepaid terms |
| $89 sale price (WellMedr) | Sale, with its end date if stated | $89 while the sale runs |
| Any $199 annual membership | Required fee | Adds $16.58 |
Two rules sit on top. First, when the price changes with the dose, each tier is recorded, and annual cost uses the maintenance tier. Second, brand prices are counted per fill under their own conditions. Lilly's $449 Zepbound KwikPen price needs each refill within 45 days and is capped at 11 fills a calendar year, so we never multiply it by twelve. Brand and compounded figures are never ranked against each other.
What disqualifies a provider from ranking
These problems stop a price from being used in a ranking or a comparison:
- It came from a third party. Since COR-008, figures from other review sites are labelled third-party claims. They are never ranked, summed or compared, however many sites repeat them. COR-009 explains why agreement between sites is not confirmation.
- It has no term, dose or date. A number without these cannot be classified, so it is not used.
- It has expired. A figure past its next-review date is marked outdated. Of the 28 records in the October 15, 2026 index, five are older records and carry their own dates.
- It cannot be confirmed. A price a provider sends us privately stays labelled provider-reported until we can read it on the provider's own page.
- It was offered for payment. No provider can pay to have a price shown, hidden or reworded.
Changes to this rubric
Prices change more often than the rubric, so the rules for handling them are versioned and dated too.
- Re-reads. The full price index was last re-read on October 15, 2026. Twenty-three of 33 programs were read on the sellers' pages that day. NexLife's prices were read on November 6, 2026. When a re-read changes a figure, the new figure is dated and the old one stays in the records.
- Rule changes. A change to how prices are classified or converted is applied to every record, not only to new ones. All monthly equivalents and annual costs are then recomputed.
- Logged precedents. COR-008 created the third-party claim label. COR-009 withdrew a figure four sites agreed on. COR-010 replaced a third-party brand price with Lilly's own.
Every rule change is dated in the methodology and dataset changelog. Corrections to published figures are on the corrections log.
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
Related on this site
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- About Tirzepatide RankedCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Mochi Health Tirzepatide ReviewProviders
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
- Eden Tirzepatide ReviewProviders
Related coverage
Tirzepatide Ranked. “GLP-1 Pricing Verification Methodology.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/pricing-verification-methodology/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.